Jennifer Moody, PhD
HEAD, INNOVATION STRATEGY, CELL THERAPY, DANAHER CORPORATION
Washington, District of Columbia, United States
Jennifer Moody has 17 years of industry experience focused on enabling cell and gene therapies. Her experience has spanned the value chain from reagent development and raw material sourcing through therapeutic product development. Her expertise includes cell and gene therapy, business operations, technical diligence, alliances and partnerships. She is currently at Head of Innovation Strategy, Cell Therapy at Danaher Corporation, and is based in Toronto, Canada. Previous roles include Gene Therapy Market Development at Pall Corporation, key operational positions at iPSC derived-cell therapy therapeutic startups, Morphocell Technologies and Bluerock Therapeutics, Business Development and technology diligence leadership at the Centre for the Commercialization of Regenerative Medicine and R&D at STEMCELL Technologies. She is a stem cell scientist by training, having completed a PhD in Genetics from the University of British Columbia in Vancouver and a postdoc studying hematopoietic stem cells at the Lund Stem Cell Center in Lund, Sweden. Selected for the Pfizer-sponsored AdMare Executive Leadership training program (2019 cohort), Jennifer also serves on the Manufacturing, Clinical Translation, and Industry Committee of ISSCR and the Business Development & Finance Committee of ISCT.
11:00 AM - 12:00 PM (PDT)
Tuesday, June 14
Genomic medicines continues to move to the forefront with an expected growth to $95B in 2028 (from …